Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Clinical trial NCT02439138 · TERMINATED

Trial details

NCT number: NCT02439138
Sponsor: Dana-Farber Cancer Institute
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Waldenstrom's Macroglobulinemia

Start date: 2015-10-01
Primary completion: 2016-04-01
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.